Internal Medicine
Latest news
324 articles · 20 / page
Moving Beyond Injectables: SOR102 Shows Promise as an Oral Dual-Inhibitor for Ulcerative Colitis
A Phase 1 trial of SOR102, a first-in-class oral bispecific antibody targeting TNF and IL-23, demonstrates favorable safety and preliminary clinical activity in patients with ulcerative colitis, suggesting a potential shift toward localized
Tofacitinib Reverses Muscle Loss in Rheumatoid Arthritis: Insights from the RAMUS Trial
The RAMUS study demonstrates that the JAK inhibitor tofacitinib significantly increases lower limb muscle volume in patients with rheumatoid arthritis, offering a potential explanation for associated creatinine elevations and a new therapeu
Tofacitinib and Muscle Volume: A Potential Paradigm Shift in Managing Rheumatoid Cachexia
The RAMUS study demonstrates that tofacitinib significantly increases lower limb muscle volume in rheumatoid arthritis patients, potentially explaining associated creatinine elevations and offering a new therapeutic avenue for combating mus
Precision Diabetology Validated: Algorithm for SGLT2i and DPP4i Selection Performs Accurately Across Major UK Ethnicity Groups
A retrospective cohort study validates an algorithm for choosing between SGLT2 and DPP4 inhibitors across diverse UK ethnicity groups, confirming its accuracy for precision medicine while highlighting the necessity of minor recalibration to
Five-Year Durability of Etranacogene Dezaparvovec: Redefining the Long-term Management of Hemophilia B
The final 5-year analysis of the HOPE-B trial confirms that etranacogene dezaparvovec provides stable, long-term factor IX expression and clinical protection for patients with hemophilia B, effectively eliminating the need for routine proph
Short-Course Ianalumab Combined with Eltrombopag: A Potential Shift Toward Sustained Remission in Immune Thrombocytopenia
The VAYHIT2 Phase 3 trial demonstrates that adding the BAFF-R monoclonal antibody ianalumab to eltrombopag significantly extends treatment-free intervals and improves stable response rates in patients with relapsed or refractory immune thro
B-Cell Depletion Meets TPO-RA: Ianalumab and Eltrombopag Redefine Treatment Success in Immune Thrombocytopenia
The Phase 3 VAYHIT2 trial reveals that combining ianalumab with eltrombopag significantly extends freedom from treatment failure and increases stable response rates in patients with second-line immune thrombocytopenia, potentially offering
Riboflavin and Blood Pressure: Evidence Remains Uncertain Despite Genetic Promise
Cochrane review shows uncertain effects of riboflavin on blood pressure, highlighting a need for larger and better-quality trials.
Aspirin in the Healthy Elderly: ASPREE’s Clear Message — No Benefit, Higher Bleeding, and Unexpected Cancer Signal
ASPREE randomized ~19,000 older adults to low‑dose aspirin or placebo. Over ~4.7 years, aspirin did not improve disability‑free survival or reduce cardiovascular events, increased major bleeding, and showed a surprising rise in cancer‑relat
Continuing Anticoagulation After Unprovoked VTE Lowers Recurrence but Raises Bleeding — Real‑World Target Trial Emulation Shows Net Clinical Benefit
A large target‑trial emulation of US claims data found continued oral anticoagulation after ≥90 days for unprovoked VTE markedly reduced recurrent VTE and mortality, increased major bleeding, but produced an overall net clinical benefit tha
Mobile Integrated Health vs Transitions of Care in Heart Failure: Insights from the Mighty-Heart Trial
A large clinical trial compared Mobile Integrated Health with standard care coordination for heart failure patients after hospital discharge, finding no significant overall benefits but highlighting potential age-related effects.
Remote Cognitive Training, Structured Rehabilitation and tDCS Failed to Improve Self‑Reported Cognitive Symptoms in Long COVID: Results from a 5‑Arm Phase 2 Randomized Trial
A multicenter phase 2 randomized trial found no differential benefit of adaptive computerized cognitive training, structured cognitive rehabilitation, or transcranial direct current stimulation (tDCS) versus active comparators for self‑repo
The Vanishing Female Survival Advantage in Stage 5 CKD: Higher Mortality and Lower Receipt of Kidney Replacement Therapy Among Women
In a population-based Alberta cohort, women with incident stage 5 CKD lost the usual female survival advantage: younger women had substantially higher excess mortality than men and were less likely to receive transplants or dialysis, indepe
Metformin Selectively Lowers Vitamin B12 but Not Other Vitamin Levels: Clinical Implications for Long-Term Therapy
A 200‑patient cross‑sectional study found metformin use tripled the odds of vitamin B12 deficiency without affecting vitamins A, B1, B6, B9, C or E, highlighting the need for targeted B12 monitoring in long‑term metformin therapy.
Quadpill or Dual Therapy for hypertension? Emerging Consensus After QUARTET — What Clinicians and Patients Should Know
Summarizes emerging expert consensus on ultra‑low‑dose quadruple antihypertensive therapy (the “quadpill”) after QUARTET and related evidence, with practical recommendations and caveats for clinical use.
Clinical Decision Support Tool May Improve ACEI and ARB Use in CKD
A personalized clinical decision support tool increased 30‑day reinitiation of ACE inhibitors or ARBs from 13% to 18% among veterans with CKD; benefits were modest and limited by population and implementation factors.
Remote Ischemic Conditioning Lowers Systolic Blood Pressure in Uncontrolled Essential Hypertension: Results of the RICBP‑EH Randomised Trial
A single‑centre randomized trial in China found that 7 days of remote ischemic conditioning (RIC) reduced average systolic BP by about 4.8 mm Hg versus sham in patients with essential hypertension (SBP ≥140 mm Hg), with good tolerability.
Home‑Delivered DASH Groceries Lower Blood Pressure and LDL in Black Urban Residents — but Benefits Fade After Support Ends
The GoFresh randomized trial found that 12 weeks of home‑delivered DASH‑patterned groceries plus dietitian counseling reduced systolic BP by 3.4 mm Hg versus cash stipends and lowered LDL; effects were not sustained three months after the i
Metformin Does Not Improve Walking Distance in Peripheral Artery Disease: Results from the PERMET Randomized Trial
The PERMET randomized, double-blind trial found that 6 months of metformin did not improve 6-minute walk distance or other functional endpoints in people with lower extremity peripheral artery disease (PAD) without diabetes.
Each Hour Sitting Counts: Sedentary Time Linked to Lower Intrinsic Capacity and Faster Decline in Older Adults
In a prospective Beijing cohort (BLINDSCE), each additional hour of daily sedentary time was associated with a 1.18-point lower baseline intrinsic capacity and a 0.48-point greater decline over 1 year, suggesting sedentary behavior is a mod
Browse by specialty
Open language-specific specialty feeds and department pages.